Home Companies Catalysts Deep Dives

MASH

MASH · CVRM · 2 drugs · 2 indications

Metabolic dysfunction-associated steatohepatitis (formerly NASH). Fatty liver with inflammation.
Competitive Landscape (2 drugs)
DrugCompanyMechanismModalityRouteStage
PegozaferminROG.SWFGF21 AnaloguePegylated FGF21SCPHASE3
AZD9550AZN—Small moleculeORALPHASE2
Indications (2)
NASH/Metabolic disease
AZD9550 PHASE1
MASH (Metabolic Steatohepatitis)
Pegozafermin PHASE3
Upcoming Catalysts
Pegozafermin - MASH - Ph3 - ToplineCLINICAL
ROG.SW2027-2028
Data from Supabase · Updated 2026-03-24